13D Filings
INTEGRATED BIOPHARMA INC
INBP
Amendment
Ownership

0.00%

Total Shares

0

Issuer CIK

1016504

Event Date

Apr 14, 2026

Accepted

Apr 17, 2026, 04:17 PM

Reporting Persons (3)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
DESANTIS CARL
Individual
0.00%000
CD Financial, LLC
Other
0.00%000
CDS Group Holdings, L.L.C.
Other
0.00%000
Disclosure Items (7)

Security Title

Common Stock, Par value $.002

Issuer Name

INTEGRATED BIOPHARMA INC

Issuer Address

225 LONG AVENUE, HILLSIDE, NJ, 07205

Filing Persons

This amendment No. 4 (this "Amendment") relates to the shares of common stock, par value $0.002 per share (the "Common Stock") of Integrated BioPharma, Inc., a Delaware corporation (the "Issuer"). This Amendment amends only the information previously reported with respect to Carl DeSantis, CD Financial, LLC, and CDS Group Holdings, L.L.C. (the "Reporting Persons") in the Statement of Beneficial Ownership on Schedule 13D, originally filed by Trade Investment Services, LLC, EVJ, LLC, EGK, LLC, CDS International Holdings, Inc., Robert B. Kay, E. Gerald Kay and Carl DeSantis with the Securities and Exchange Commission (the "Commission") on March 28, 2003, as amended by Amendment 1, filed with the Commission on July 22, 2003, Amendment No. 2, filed with the Commission on December 20, 2006, and Amendment No. 3, filed with the Commission on August 12, 2008. This Amendment is being filed to report that as of April 15, 2026, the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of the Issuer and have exited Section 13 reporting status. The Issuer's principal executive offices are located at 225 Long Avenue, Hillside, New Jersey 07205. The Names of the Reporting Persons are: i. CD Financial, LLC, a Florida limited liability company ("CD") ii. CDS Group Holdings, L.L.C., a Florida limited liability company ("CDS") iii. Carl DeSantis, a deceased individual ("DeSantis", and, together with CD and CDS, the "Group")

Business Address

i. CD: 109 SE 5th Avenue Second Floor, Delray Beach, FL 33483 ii. CDS: 109 SE 5th Avenue Second Floor, Delray Beach, FL 33483 iii. DeSantis: C/O, Estate Representative, 109 SE 5th Avenue, Second Floor, Delray Beach, FL 33483

Principal Occupation

i. CD: N/A ii. CDS: N/A iii. DeSantis - deceased. The prior occupation of the Reporting Person was Chairman of CDS International Holdings, Inc.

Convictions

During the last five years, no member of the Group has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Citizenship

i. CD: Florida ii. CDS: Florida iii. DeSantis - deceased. United States

Not applicable. This Amendment reports the cessation of beneficial ownership of the Reporting Persons due to the death of DeSantis and the transfer described in Item 4.

As a result of the death of DeSantis on August 10, 2023, all of the Group's shares of Common Stock of the Issuer were transferred to CDDS 2.0, LLC, a Florida limited liability Company, wholly owned by DeSantis's beneficiary, Damon DeSantis, on March 24, 2026, March 30, 2026 and April 15, 2026 (the "Transfer"). Following the final Transfer of shares of Common Stock, the Group ceased to be the beneficial owner of any shares of Common Stock of the Issuer. The Group, including the estate of DeSantis, has no present plans or proposals which relate to or would result in any of the matters set forth in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Percentage of Class

The Group beneficially owns 0 shares of Common Stock, representing 0.0% of the class of shares of Common Stock subject hereof.

Number of Shares

The Group has no sole or shared voting or dispositive power with respect to the shares of Common Stock.

Transactions

Except for the transactions described in Item 4, the Group has not effected any transaction in the shares of Common Stock subject hereof during the sixty (60) days prior to the date of this Amendment.

Shareholders

Immediately following the Transfer, CDDS 2.0, LLC owned more than five percent of the shares of Common Stock of the Issuer. CDDS 2.0, LLC is a Florida limited liability company controlled by Damon DeSantis. As a result, CDDS 2.0, LLC directly, and Damon DeSantis indirectly, beneficially own more than five percent of the shares of Common Stock of the Issuer.

Date of 5% Ownership

The Group ceased to be a beneficial owner of the shares of Common Stock subject hereof on April 15, 2026.

The Reporting Persons do not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder?s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

99.1 Joint Filing Agreement, as required by Rule 13d-1 (k) under the Securities Exchange Act of 1934, as amended.

INTEGRATED BIOPHARMA INC — Schedule 13D | 13D Filings